Akers Biosciences Profit Margin

The latest profit margin for AKER is -3948.27% as of December 2020. That compares with -369.23% in the prior-year period — down 969.3% year over year. That is below the Healthcare sector average of 13.45%. Investors often review this figure alongside Akers Biosciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, AKER's profit margin moved from -369.23% to -3948.27% — a 969.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Akers Biosciences's valuation or profitability profile.

Against Healthcare companies, AKER currently prints -3948.27% for profit margin, while the sector average sits near 13.45%. That is roughly 29460.0% below the sector mean. Large gaps often invite a closer look at Akers Biosciences's growth, margins, and balance sheet.

Profit Margin shows how effectively Akers Biosciences converts resources into returns. At -3948.27%, AKER may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -369.23% in the prior-year period — down 969.3% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting AKER's profit margin (-3948.27%), review year-over-year change from -369.23%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.